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Abstract 
 
Aims: Rapid blood vessel ingrowth in transplanted tissue engineering constructs is the key 
factor for successful incorporation, but many potential patients who may use engineered 
tissues suffer from widespread diseases that limit the capacity of neovascularization (e.g. 
diabetes). Thus, in vivo vascularization analyses of tissue-engineered constructs in 
angiogenically affected organisms are required.  
Methods: We therefore investigated the in vivo incorporation of collagen-coated and cell-
seeded poly-L-lactide-co-glycolide scaffolds in diabetic B6.BKS(D)-Leprdb/J mice using 
repetitive intravital fluorescence microscopy over a time period of two weeks. For this 
purpose, scaffolds were seeded with osteoblast-like or bone marrow mesenchymal stem cells 
and implanted into the dorsal skinfold chambers of diabetic and non-diabetic (C57BL/6) mice.  
Results: Apart from slightly increased inflammatory parameters, diabetic mice showed 
significantly reduced capillary densities compared with non-diabetic animals from day 6 
onward. In line with previous studies, more densely meshed microvascular networks were 
demonstrated in cell-seeded than in collagen-coated scaffolds from day 6 onward within the 
single groups (diabetic and control).  
Conclusions: A large number of patients who suffer from systemic diseases that affect 
angiogenesis would profit from tissue engineering. Therefore, the challenge for the clinical 
introduction of tissue-engineered constructs will be to overcome the decreased angiogenesis 
in diabetic organisms.  
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1. Introduction 
 
Over the past years, tissue engineering has made considerable progress in the replacement and 
reconstruction of various tissues. In this process, the vitalization of suitable scaffolds with 
pluripotent cells (e.g. bone marrow mesenchymal stem cells, bmMSCs) or organ-specific cells 
(e.g. osteoblast-like cells, OLCs) represents the basic principle [1]. A vital requirement for the 
successful incorporation of tissue-engineered constructs is rapid vascularization of the 
transplants. An adequate blood supply is indispensable to satisfy the metabolic demands of 
the seeded cells concerning the provision of oxygen and nutrients as well as waste disposal 
[2]. 
To accelerate vascularization in tissue-engineered constructs seeded with cells, various 
strategies have been performed, in some cases with remarkable results. Single growth factors, 
especially vascular endothelial growth factor (VEGF) [3, 4], have been applied as well as 
combinations of different growth factors [5]. A positive effect on vascularization in tissue-
engineered constructs has been demonstrated in co-cultures of different endothelial cell 
lineages and osteoblasts [6, 7] and in co-cultures of bmMSCs and OLCs [6, 8]. Additional 
strategies have been generated to prefabricate vascular structures in tissue-engineered 
constructs [9, 10].  
Several of these studies have been conducted using healthy animals. This could be an 
elementary problem for the transfer into the clinic because many potential patients who may 
use tissue-engineered constructs suffer from diseases that limit the capacity of 
neovascularization, e.g. diabetes or hypertonia [11]. In the year 2011, approximately 366 
million people suffered from diabetes worldwide. By 2030, this number will have grown to 
approximately 552 million people (International Diabetes Federation = IDF [12]). Therein, at 
least 90% are represented by type 2 diabetes [12]. Regarding neovascularization, diabetes 
plays a special role. On one hand, exorbitant vascularization can be observed (e.g. diabetic 
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retinopathy and nephropathy), but on the other hand, decreased neovascularization is apparent 
(e.g. diabetic foot syndrome, reduced wound healing, and graft rejection) [13]. This 
phenomenon is called the “diabetic paradox” [14]. Concerning the deregulated 
neovascularization caused by diabetes, more than 100 contributing factors are known [15]. 
Amongst others, the dysregulation of growth factors such as VEGF, insulin-like growth factor 
(IGF), and nitric oxide synthase 2 have been described. 
Herein, we elucidate directly the in vivo vascularization capacity of tissue-engineered 
constructs in a diabetic organism. For this purpose, poly-L-lactide-co-glycolide (PLGA) 
scaffolds were seeded with organ-specific cells (OLCs) or undifferentiated progenitor cells 
(bmMSCs) and implanted into the dorsal skinfold chambers of diabetic B6.BKS(D)-Leprdb/J 
mice. C57BL/6 mice served as controls. After transplantation of the tissue-engineered 
constructs, we analyzed the angiogenic and inflammatory parameters using repetitive 
intravital fluorescence microscopy over a time period of two weeks. 
 
 
2. Materials and Methods 
 
2.1 Animals  
The experiments were conducted in accordance with the German legislation for the protection 
of animals and the NIH Guidelines for the Care and Use of Laboratory Animals (NIH 
Publication No. 85-23 Rev. 1985). The experiments were approved by the local governmental 
animal care committee (Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit, reference number 33.9-42502-04-08/1437). Male diabetic 
B6.BKS(D)-Leprdb/J mice with a homozygous mutation of the leptin receptor (recessive 
heredity) were used for the experiments at the age of 13–16 weeks and a body weight of 35–
49 g (Jackson Laboratories, Bar Harbor, USA). This mouse strain is characterized by the 
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development of type 2 diabetes. From the age of two weeks, their level of insulin increases. 
From the third to fourth week, obesity starts [16] and the blood glucose level begins to rise 
between the fourth and eighth week [17]. The mice show polyphagia, polydipsia, and polyuria 
as well as a compensatory hyperplasia of the pancreatic beta cells with hyperinsulinemia [17]. 
Wound healing is delayed, metabolic efficiency is increased [18, 19], a hypertrophy of the left 
ventricle is described [16], and the number of blood leukocytes is decreased [20]. 
Male C57BL/6 (C57Black) mice at the age of 8–15 weeks and a body weight of 18–22 g 
(WIGA Charles River, Sulzfeld, Germany) were used as controls. This strain represents the 
genetic background of the B6.BKS(D)-Leprdb strain. All animals were housed at one per cage 
at room temperature (22–24°C) at a relative humidity of 60–65% in a 12 h day–night cycle. 
The animals had free access to tap water and standard pellet food (Altromin, Lage, Germany) 
throughout the experiment.  
 
2.2 Preparation of the dorsal skinfold chamber  
Both surgery and repetitive intravital fluorescence microscopy were performed under 
anesthesia by intraperitoneal injection of 0.1 mL of saline solution (Sigma, Steinheim, 
Germany) per 10 g of body weight. The saline solution contained 90 mg/kg body weight 
ketamine hydrochloride (Ketavet®; Parke Davis, Freiburg, Germany) and 25 mg/kg body 
weight dihydroxylidinothiazine hydrochloride (Rompun®; Bayer, Leverkusen, Germany). 
The dorsal skinfold chamber allowed intravital microscopic surveillance of microcirculation 
in the anesthetized animal over an extended period. The surgical technique for the preparation 
of the dorsal skinfold chamber and its implantation have been described previously [21].  
PLGA scaffolds where implanted into the dorsal skinfold chamber after a recovery period of a 
minimum of 48 h subsequent to preparation. For this purpose, animals were anesthetized as 
described before. The cover slip was removed, and the implant was placed on the striated 
muscle in the center of the chamber. After the implantation, the chamber was resealed. 
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2.3 Fabrication of tissue-engineered constructs 
PLGA scaffolds of 3 × 3 × 1 mm were fabricated in the Freiburg Institute for Material 
Research and Macromolecular Chemistry using 3D BioplotterTM operated by the PRIMCAM 
software (PRIMUS DATA, Einsiedeln, Switzerland) as previously described [22]. 
To prepare PLGA scaffolds with OLCs, cells were isolated from male C57BL/6 mice aged at 
6–8 weeks as presented recently [8]. The mice were euthanized by CO2-Inhalation and 
washed with 70% ethanol (J.T. Baker, Phillipsburg, USA). The frontal and parietal calvaria 
were removed and sharp dissected free of any adherent tissue. The cleaned bone fragments 
were kept in HBSS (PAA, Coelbe, Gemany) on ice until cell isolation. After mincing bone 
fragments to pieces of approximately 3x3 mm, cells were isolated using 200 U/ml collagenase 
II (Cell Systems, St. Katharinen, Germany) in HBSS. Pools of 10 calvarias were digested five 
times with 5 ml enzyme solution at 37 °C for 10 min with a shaking rate of 150 rpm. The 
supernatants of digestion 3, 4 and 5 were pooled, pelleted by centrifugation (1200 rpm, 7 min) 
and washed twice with culture medium (DMEM: 10% fetal calf serum, 20 mM Hepes, 1000 
IU/ml penicillin and 0.1 mg/ml streptomycin; PAA, Pasching, Austria). Isolated cells were 
plated on 100 mm cell culture dishes (Greiner, Frickenhausen, Germany) with DMEM and 
incubated at 37° C in a humidified incubator with an atmosphere of 91.5% air, 8.5% CO2 
until confluent. Media were changed every 3rd day unless otherwise specified. To prepare 
secondary subcultures from these cells, the cell layers were gently rinsed with HBSS (PAA) 
and then incubated with accutase (PAA). Cells released from the culture surface were washed 
twice with culture medium and aliquoted on new 100 mm cell culture dishes at the desired 
plating density. Secondary passage cells were characterized by immunocytochemistry. 
Bone marrow-derived murine mesenchymal stem cells were isolated according to established 
protocols based on plastic adherence of these cells [8, 23, 24]. In addition, bone marrow was 
obtained from male C57BL/6 mice aged at 6–8 weeks. Femurs and tibias were dissected free 
of surrounding tissue and bone marrow was flushed out with HBSS containing 1000 U/ml 
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Heparin (Sigma, Steinheim, Germany). The resulting bone marrow was disrupted by passing 
through a 20-gauge needle, centrifuged at 300 xg for 7 min and resuspended in 3 ml DMEM. 
The cell suspension was applied to a density gradient (LSM 1077, 1,077g/ml; PAA) [25] and 
centrifuged again (500 xg, 30 min). The interphase containing bone marrow derived 
mononuclear cells was transferred to a 15-ml tube (BD Biosciences, Erembodegem, Belgium) 
and washed three times with 10 ml DMEM (10% FCS). Cells were plated at a density of 1 x 105 
on cell culture dishes (100 mm; Greiner) and incubated at 37° C in a humidified incubator with 
an atmosphere of 95% air, 5% CO2 until confluent. Media were changed every 3rd day unless 
otherwise specified. Culture medium was MesenCult (StemCell Technologies, Köln, Germany). 
To prepare secondary subcultures from these cells, the cell layers were gently rinsed with HBSS 
(PAA) and then incubated with Trypsin/EDTA (PAA). Cells released from the culture surface 
were washed with two changes of culture medium, and aliquoted on new 100 mm cell culture 
dishes at the desired plating density. Secondary passage cells were characterized by 
immunocytochemistry.  
For characterization cells were fixed with 4% paraformaldehyd (Sigma) for 10 min. After 
blocking for 20 min with PBS (Central pharmacy, Hannover Medical School) containing 5% 
FCS (PAA) and 0.2% Tween (Sigma), cells were incubated with primary antibodies overnight 
at 4°C and subsequently with secondary antibodies for one hour. Between each step cells were 
washed three times with PBS for 5min. OLCs were characterized with  rabbit anti-mouse 
collagen I (Biotrend, Köln, Germany), rabbit anti-mouse osteocalcin (Acris Antibodies GmbH, 
Hiddenhausen, Germany) and rat anti-mouse osteonectin (SPARC, R&D Systems, Wiesbaden, 
Germany) [26]. Mesenchymal stem cells were characterized with anti-mouse Ly-6A/E (Sca-1) 
(Biolegend, San Diego, USA) and anti-mouse CD44 (Biolegend) [24]. Cy 2 conjugated goat 
anti-rabbit antibody and Cy 2 conjugated goat anti-rat antibody (both Dianova, Hamburg, 
Germany) were used as secondary antibodies. Nuclei were stained using DAPI (Sigma). Cells 
were examined by fluorescence microscopy (DM4000B Leica Mikrosysteme, Wetzlar, 
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Germany). For additional characterisation of OLCs, histochemical alkaline phosphatase 
determination was performed; cells were washed three times with HBSS and incubated for 15 
minutes in 5-Bromine-4-Chlorine-3-Indolyl phosphate/nitro blue tetrazolium (BCIP/NBT 
tablets, Roche, Mannheim, Germany) [27]. Cells were examined by light microscopy 
(DM4000B Leica Mikrosysteme) without counterstaining. 
For in vivo experiments, PLGA scaffolds were coated with collagen type I corresponding to 
standardized guidelines [8]. Cultivated cells were rinsed three times with HBSS and then 
incubated with accutase (OLCs) or Trypsin/EDTA (bmMSCs) (PAA, Coelbe, Germany) until 
cells were released from the culture surface. Cells were washed twice with culture medium 
and counted. Subsequently, 1 × 104 OLCs or bmMSCs were resuspended in 10 μL of culture 
medium and spotted onto the PLGA scaffolds coated with collagen type I. The scaffolds with 
cells were incubated at 37 °C in a humidified incubator in an atmosphere with 91.5% air and 
8.5% CO2 for 4 h to ensure cell attachment to the scaffold surfaces. Scaffolds with attached 
cells were placed in fresh culture medium and incubated overnight at 37 °C in a humidified 
incubator in an atmosphere with 95% air and 5% CO2. Afterwards, the prepared scaffolds 
were implanted into the dorsal skinfold chambers of B6.BKS(D)-Leprdb/J and C57BL/6 mice. 
 
2.4 Intravital fluorescence microscopy 
For in vivo fluorescence microscopy, mice were anaesthetized and immobilized with a 
custom-made stereotactic frame (Central Research Laboratory, Hannover Medical School). 
After intravenous injection of 0.1 mL of 5% fluorescein isothiocyanate (FITC)-labeled 
dextran 150,000 (Sigma) (for contrast enhancement by staining of blood plasma) and 0.1 mL 
of 0.1% rhodamine 6G (Sigma) (for direct staining of white blood cells), intravital 
fluorescence microscopy was performed using a modified Zeiss Axiotech microscope 
equipped with a 100 W mercury lamp attached to an illuminator with blue, green and 
ultraviolet filter blocks (Zeiss, Jena, Germany) for epi-illumination. The microscopic images 
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were recorded by a charge-coupled device video camera (FK-6990, COHU, Prospective 
Measurements, San Diego, USA) and transferred to a DVD recorder (LQ- MS 800, 
Panasonic, Hamburg, Germany) for off-line evaluation. With the use of 10x and 20x long 
distance objectives the images were displayed on a 14 inch video screen (Panasonic, DVD 
video recorder LQ-MD 800E, Matsushita Electronic Industrial Co Ltd., Osaka, Japan). 
 
2.5 Microcirculatory analysis 
Quantitative off-line analysis of the DVDs was performed by means of the computer-assisted 
image analysis system CapImage (Zeintl, Heidelberg, Germany). Leukocyte-endothelial cell 
interaction, microhemodynamics and macromolecular leakage were assessed at a 
magnification of 20x in 4 different microvascular regions of interest (ROIs) in the border zone 
of the scaffolds. In each ROI, 1-3 venules (inner diameter: 20-40 µm) were selected for 
measurements. Leukocytes were classified according to their interaction with the vascular 
endothelium as adherent, rolling or free-flowing cells as described previously [28]. Adherent 
leukocytes were defined in each vessel segment as cells that did not move or detach from the 
endothelial lining within a specified observation period of 20s, and are given as number of 
cells per square millimeter of endothelial surface, calculated from the diameter and length of 
the vessel segment studied, assuming a cylindrical vessel geometry [29]. Rolling leukocytes 
were defined as cells moving with a velocity less than two-fifths of the centerline velocity, 
and are given as number of cells per minute, passing a reference point within the microvessel. 
Diameters, centerline velocity, volumetric blood flow, and wall shear rate were determined in 
those venules in which leukocyte-endothelial cell interaction was analyzed. Diameters (d) 
were measured in μm perpendicularly to the vessel path. Centerline red blood cell velocity (v) 
was analyzed by the computer-assisted image analysis system using the line shift method. 
Volumetric blood flow was calculated by Q = π x (d/2)2 x v/1.6 (pl/ s), where 1.6 represents 
the Baker-Wayland factor to correct for the parabolic velocity profile in microvessels with 
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diameters >20 μm [30]. Wall shear rate (y) was calculated based on the Newtonian definition: 
y = 8 x v/ d. Macromolecular leakage served as an indicator for microvascular permeability 
and was assessed after an intravenous injection of the macromolecular fluorescent dye FITC-
labeled dextran 150.000 by densitometrically determining the grey levels in the tissue directly 
adjacent to the venular vessel wall (E1), as well as in the marginal cell-free plasma layer 
within the vessel (E2). Extravasation (E) was then calculated as E = E1 / E2.  
Angiogenesis was assessed in 200x magnification. For this purpose, functional microvessel 
density was measured quantitatively in 8 regions of interest (ROI) in the border zone of the 
scaffolds and in 4 regions of interest (ROI) in the center of the scaffolds. Microvessels which 
showed a distinct ingrowth, i.e. new capillary buds and sprouts, were counted. By computer 
assisted analysis using the CapImage software, cumulative length of microvessels per 
observation area given in cm/cm2 was calculated [31]. For microcirculatory analysis 
investigators were blinded to the treatment group.  
 
2.6 Experimental protocol 
The weight of the mice was measured before preparing the dorsal skinfold chamber and every 
time before performing microcirculatory analysis. 
For intravital fluorescence microscopy, 24 B6.BKS(D)-Leprdb/J mice were randomly divided 
into three groups with eight animals in each group. Each group was equipped with dorsal 
skinfold chambers. The PLGA scaffolds were coated with collagen (n = 8), coated with 
collagen and seeded with OLCs (n = 8), or coated with collagen and seeded with bmMSCs (n 
= 8), and then implanted. 24 C57BL/6 mice, also randomly divided into three groups with 
eight animals in each group, served as controls. During implantation, care was taken to avoid 
contamination, mechanical disruption, and chamber damage. The macroscopic appearance of 
the skinfold chamber preparations and the implanted tissue-engineered constructs were 
documented daily. Intravital fluorescence microscopy of the microhemodynamics, leukocyte-
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endothelial cell interaction, macromolecular leakage, and angiogenesis was performed 
immediately and 3, 6, 10, and 14 days after the implantation. 
At the end of the in vivo experiments, the animals were killed with an overdose of the 
anesthetic, and the dorsal skinfold preparations were sacrificed for histological examination.  
 
2.7 Histology and immunohistochemistry 
At the end of the in vivo experiments, histological examinations of the dorsal skinfold 
chamber preparations were performed. For light microscopy, formalin-fixed (Merck KGaA, 
Darmstadt, Germany) specimens of the dorsal skinfold chamber preparations were embedded 
in paraffin (Leica Mikrosysteme, Wetzlar, Germany). Five-micrometer thick sections were cut 
and stained with hematoxylin and eosin (HE, both Merck KGaA) according to standard 
procedures and examined by light microscopy (DM4000B, Leica Mikrosysteme). 
For immunohistochemical detection of CD31, as evidence for the presence of endothelial 
cells, formalin-fixed specimens from the dorsal skinfold chamber were embedded in paraffin 
and cut into 5-μm thick sections. Consecutive sections were incubated with a rabbit anti-
mouse CD31 antibody (Acris Antibodies GmbH, Hiddenhausen, Germany). A biotin-
conjugated goat anti-rabbit antibody (Dianova, Hamburg, Germany) was used as secondary 
antibody. Incubation with streptavidin-horseradish peroxidase (Dianova) was followed by 
color development with aminoethylcarbazole (AEC) substrate (Axxora Deutschland GmbH, 
Loerrach, Germany) at room temperature. Color development was stopped under microscopic 
control by washing with water. The sections were counterstained with hemalaun (Merck 
KGaA) and examined by light microscopy (DM4000B, Leica). For negative control the 
primary antibody was omitted. 
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2.8 Statistics 
Results are expressed as means ± SEM. Differences between groups were assessed by one-
way ANOVA and differences within each group were analyzed by one-way ANOVA with 
repeated measures. To isolate overall differences, appropriate Student-Newman-Keuls or 
Dunn post-hoc tests were performed. Differences were considered significant at p < 0.05.  
 
 
3. Results 
 
3.1 Gain / loss of weight 
Significant differences in the gain or loss of weight were not detected in control and diabetic 
mice throughout the 14-day observation period (data not shown). 
 
3.2 Microhemodynamics 
Microhemodynamic parameters were constant and comparable in all experimental groups at 
any point in time. Values concerning venular diameters, volumetric blood flow, and wall 
shear rates were measured in postcapillary and collecting venules in direct vicinity to the 
scaffolds immediately as well as 3, 6, 10, and 14 days after scaffold implantation. The 
diameters ranged from 20 to 40 µm, and no significant differences could be observed in 
volumetric blood flow and wall shear rates between the groups throughout the entire 
experiment (data not shown).  
 
3.3 Inflammatory response 
All experimental groups showed a discreet inflammatory response on day 3 after scaffold 
implantation, represented by a slight increase in rolling and adherent leukocytes as well as a 
marginal increase in the microvascular permeability, illustrated by the macromolecular 
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leakage in the postcapillary venules at the border zones of the scaffolds (Fig. 1). The diabetic 
groups showed slightly higher inflammatory reactions compared with the controls. However, 
none of the values increased any further, and all values were comparable and constant at any 
point in time up to day 14 (Fig. 1). For all parameters significant differences could not be 
detected throughout the entire 14-day observation period. 
 
3.4 Angiogenesis and neovascularization 
Typical signs of angiogenesis are characterized by the dilation of capillaries and the formation 
of capillary buds and sprouts, primarily originating from the venular segments of the striated 
muscle capillaries and postcapillary venules of the host tissue. These signs of 
neovascularization could be detected in all experimental groups for the first time on day 3. 
During the experimental period, these sprouts protruded from both the border zone toward the 
center of the scaffold and from the center to the border zone, interconnecting with each other 
and building red blood cell-perfused vascular networks with increased functional capillary 
densities (Figs. 2 and 3). Thereby the amount of newly formed microvessels was very similar 
and not significantly different between scaffold centers and border zones within the single 
groups at any point in time.   
Regarding diabetic animals and healthy controls, separate quantitative analysis of functional 
capillary density demonstrated microvascular networks that were markedly more densely 
meshed in the vitalized scaffolds than in the collagen-coated PLGA scaffolds from day 6 
onward. At any subsequent point in time, the microvascular density of the cell-seeded 
scaffolds within the diabetic or healthy group was significantly higher compared with that of 
the collagen-coated scaffolds in the equivalent group. With sole regard to the vitalized 
scaffolds, there was no significant difference between the scaffolds that were seeded with 
OLCs or bmMSCs. Throughout the entire 14-day observation period, the extent of capillary 
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density was comparable within OLC- and bmMSC-seeded scaffolds with reference to the 
diabetic and non-diabetic groups (Figs. 2 and 3).  
Comparing diabetic and healthy mice, the microvascular networks within the single diabetic 
group (collagen-coated, OLC-seeded, and bmMSC-seeded) showed a very similar time 
progress compared with the healthy controls. However, from day 6 onward, significantly 
reduced capillary densities were observed in each case at any point of examination. The trend 
of reduced microvascular densities was constant between the single diabetic and non-diabetic 
groups from day 6 up until day 14. With a view of the absolute values at the different 
moments of examination, the capillary densities of the cell-seeded scaffolds in diabetic mice 
were approximately comparable to the microvascular networks induced by the scaffolds that 
were solely coated with collagen in healthy animals (Figs. 2 and 3).  
 
3.5 Histology and immunohistochemistry 
To confirm the intravital microscopic results, histology and immunohistochemistry were 
performed. Sections from paraffin-embedded specimens at day 14 showed noticeable 
differences in the histological appearance depending on the animal group (diabetic or non-
diabetic) and the type of implanted scaffold (Fig. 4). In the collagen-coated scaffolds of 
diabetic mice, microvascular structures were barely detected. The number of capillary-like 
structures in the cell-seeded scaffolds in diabetic animals was remarkably higher than that in 
scaffolds in the absence of seeded cells, and was comparable to the microvasculature of the 
collagen-coated scaffolds in non-diabetic mice. The microvascular networks of the cell-
seeded scaffolds in healthy animals increased distinctly compared with all other scaffolds. 
Within these two groups, there was no significant difference as to whether the scaffolds were 
seeded with OLCs or bmMSCs. The identity of the visible vascular structures as microvessels 
was verified by immunohistochemical detection of the endothelial cell marker CD31 (Fig. 5). 
Results of the immunohistochemical analysis were congruent with the findings of histology. 
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4. Discussion 
 
In the present study, we proved that vascularization decelerated in tissue-engineered 
constructs in association with diabetes mellitus in vivo. After their transplantation into the 
dorsal skinfold chambers of diabetic B6.BKS(D)-Leprdb/J mice, the implants showed a 
significant decrease in the development of microvascular networks compared with non-
diabetic controls (C57BL/6 mice). This observation applied to the scaffolds seeded with 
organ-specific cells (OLCs) or undifferentiated progenitor cells (bmMSCs) as well as to the 
non-vitalized scaffolds. The cell-seeded scaffolds showed a significantly higher number of 
capillary-like structures within their particular group (diabetic and non-diabetic) from day 6 
after transplantation, a result which is in line with previous studies [8, 32]. 
Microhemodynamic parameters were constant in any group and comparable between single 
groups throughout the entire experiment. 
Concerning the selection of an appropriate mouse strain, diabetes can be induced in healthy 
animals, e.g. by injection of streptozotocin [33]. On the other hand, a strain characterized by 
genetic development of diabetes can be used. In the present study, mice with genetically 
induced diabetes were used to prevent the animals from undergoing further invasive 
examinations (permanent proof of hyperglycemia in mice with medicamentously induced 
diabetes). Since at least 90% of diabetes in humans are represented by type 2 diabetes [12], 
the study was performed with a type 2 diabetes strain. Disturbed neoangiogenesis plays a key 
role in the deranged wound healing in association with diabetes mellitus [13], and rapid 
vascularization is a basic requirement for the successful incorporation of tissue-engineered 
constructs [1]. For these reasons, a mouse strain with typical diabetic wound healing 
deficiency (B6.BKS(D)-Leprdb/J) was chosen for the experiments [11, 34]. A potential 
disadvantage could be the mutation of the leptin receptor. Leptin influences the 
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proinflammatory immune response [35] as well as T-cell functions [36], which could affect 
angiogenesis [11, 37]. 
PLGA scaffolds with a defined pore size of 250 µm have been proven as a well-suited three-
dimensional (3D) basic material for tissue-engineered constructs [8, 38]. For in vivo 
microscopic analyses, they were applied in association with the dorsal skinfold chamber 
because of the excellent comparability with previous investigations [3, 4, 8, 32]. Growth 
factors were not used in the present study, although several successful applications in diabetic 
animals have been described [39]. However, the incorporation of growth factors is extremely 
complicated as it concerns dosage and combinations [40]. Au et al. reported a regression of 
the microvascular network with the use of angiogenic growth factors in combination with 
vascular cells [41]. Also, normally proangiogenic nitric oxide showed a converse effect under 
certain conditions [40]. In particular, special attention must be given to the usage of growth 
factors in diseases like diabetes, which are characterized by exorbitant vascularization (e.g. 
diabetic retinopathy) and decreased neovascularization (e.g. diabetic foot syndrome) at the 
same time (the “diabetic paradox”) [13, 14]. In this context, the medication of growth factors 
is not terminally clarified [42]. Most remarkably, systemically applied growth factors can 
induce uncontrolled vessel growth and neoplasms in unexpected regions of the organism [43]. 
PLGA scaffolds were seeded with OLCs or bmMSCs for different reasons. A typical 
approach in tissue engineering is the application of organ-specific cells (e.g. OLCs) on one 
hand and undifferentiated progenitor cells with various differentiation capacities (e.g. 
bmMSCs) on the other hand. In particular, collagen-coated PLGA scaffolds seeded with 
OLCs or bmMSCs have been transplanted into the dorsal skinfold chamber of BALB/c mice 
in a very similar prior investigation [8], which guaranteed excellent comparability. In that 
study, the accelerated angiogenesis caused by OLCs and bmMSCs was most likely induced 
by a hypoxia-driven release of VEGF from these cells inside the tissue-engineered constructs 
rather than a dependence on the potential of bmMSCs to differentiate into specific vascular 
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cells [8]. Very little is known about OLCs for tissue engineering applications in diabetic 
animal models, whereas topical administration of mesenchymal cells seeded on collagen 
scaffolds augmented wound healing and increased angiogenesis in a diabetic rabbit ulcer [44]. 
Overall, the angiogenic effect of mesenchymal stem cells as a therapeutic target for enhancing 
diabetic wound healing has been well described [45]. In the current study, OLCs and 
bmMSCs were isolated and cultivated from the control strain because of various reports on 
the negative effects on vascularization and wound healing caused by different pluripotent 
cells of diabetic origin [13, 19]. 
With regards to the inflammatory host tissue response, diabetic mice and controls showed 
comparable results to earlier studies concerning the analyzed parameters (rolling and adherent 
leukocytes, macromolecular leakage) [4, 8, 32]. The moderate increase in these values after 
implantation of all types of scaffolds at day 3 are in line with other investigations, showing a 
local transient inflammatory tissue response after implantation of foreign materials [8, 38]. 
Compared with the controls, the diabetic groups showed slightly higher inflammatory 
reactions, but without any significant differences. Algenstaedt et al. also demonstrated higher 
numbers of rolling and adherent leukocytes in a dorsal skinfold chamber model of diabetic 
mice in comparison with controls [46]. This phenomenon was interpreted by the expression of 
adhesion molecules induced by glucose. The increased expression of endothelial adhesion 
molecules is triggered by the excessive production of advanced glycation end products 
(AGEs) during hyperglycemia [47]. Additionally, AGEs themselves cause an elevated 
oxidative stress level in endothelial cells [48, 49]. In addition, an ischemia study in diabetic 
rats showed higher numbers of rolling leukocytes in the mesenteric venules [50]. This result 
was explained by a reduced volumetric blood flow in the diabetic animals, which could not be 
detected in the present study. Overall, decreased numbers of blood leukocytes are described 
for the current diabetic mouse strain compared with healthy control animals [20]. Therefore, it 
could be assumed that the slight increase in rolling and adherent leukocytes is in fact the 
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expression of a clearer elevation of these inflammatory parameters. The moderate rise in 
macromolecular leakage is also confirmed by previous studies with diabetic mice and rats [46, 
50], e.g. Martin et al. reported the higher fluorescein permeability of newly formed capillaries 
in the diabetic retina [13].  
Rapid vascularization of tissue-engineered constructs is a vital requirement for their 
successful incorporation, but many potential users of such constructs suffer from widespread 
diseases that limit the capacity of neovascularization (e.g. diabetes). As in vivo studies of this 
problem are severely limited, special attention was given to the angiogenesis of the 
transplanted cell-seeded scaffolds in the diabetic organisms used herein. The chronological 
development of functional capillary densities in control groups was comparable to a recent 
study with the same experimental setup using healthy BALB/c mice [8]. Therefore, a 
conclusion can be drawn with considerable certainty that the accelerated angiogenesis caused 
by OLCs and bmMSCs in control groups was induced by a hypoxia-driven release of VEGF 
from the cells. Regarding the diabetic mice, microvascular networks within single groups 
showed a very similar time progress compared to healthy controls. However, significantly 
reduced capillary densities were observed from day 6 onward in each case at any point of 
examination. For that reason, it was concluded that the increased vascularization in cell-
seeded scaffolds in diabetic mice was also most likely VEGF-driven based on the hypoxia of 
the OLCs and bmMSCs in the centers of tissue-engineered constructs. The decrease in 
vascularization in diabetic animals is in line with other studies. Decelerated neoangiogenesis 
was reported in the ischemic hindlimb model of diabetic mice [11, 37]. Thereby the possible 
mechanisms underlying impaired neovascularization in the diabetic organism are highly 
diverse. Some of these mechanisms involve dysfunctioning and decrease in the number of 
endothelial progenitor cells [37]. Considerably increased differentiation of MSCs to 
adipocytes may be another reason for the reduced angiogenic capacity [37]. Concerning 
diabetic microangiopathy the thickening of the basement membrane has to be considered [49]. 
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Thus migration of cells from the vascular system, which is essential for angiogenesis, is 
hindered [13]. Lack of VEGF is also responsible for insufficient neovascularization during 
diabetic wound healing and deranged arteriogenesis [13, 18]. Impaired neovascularization in 
diabetic mice is associated with decreased concentration of fibroblast growth factor (FGF) 
[51]. In addition, many other factors are involved in disordered angiogenesis in the diabetic 
organism, including AGEs, sorbitol, angiopoietin (and its receptors), and nitrogen monoxide, 
which is crucial for the effects of VEGF, FGF, and transforming growth factor β1 [13]. The 
application of VEGF could also expedite vascularization in the ischemic hindlimb model of 
diabetic mice [52]. However, with regards to the multiple problems associated with the 
treatment with growth factors [40-43], they were not used in the current investigation. 
The presented data demonstrate that the dorsal skinfold chamber represents an excellent 
model for in vivo angiogenesis studies of tissue-engineered constructs, also in diabetic mice. 
Thus promising research results can be applied in animal models showing impairments, and 
comparative studies can be performed. For the present study this is of major interest showing 
significantly decelerated vascularization in diabetic mice compared with that in healthy 
controls. Moreover, the positive angiogenic effect of seeded OLCs and bmMSCs was most 
likely VEGF-driven due to hypoxia of the transplanted cells. The challenge for the future will 
be to compensate for the decreased angiogenesis in tissue-engineered constructs in the 
diabetic organisms. A hopeful approach could be to transplant tissue-engineered constructs 
where angiogenesis has already been initiated in vitro. Concerning this matter, several 
promising approaches have been performed recently. Compared with constructs that were not 
pre-incubated, a two-week pre-incubation period of bmMSC-seeded PLGA scaffolds in 
Matrigel led to significantly accelerated angiogenesis after transplantation in healthy animals 
[53]. Among other strategies to generate or prefabricate vascular structures in tissue-
engineered constructs by means of microfabrication of vascular networks [9, 10, 54], a culture 
system promoting the ability of HUVECs (human umbilical vein endothelial cells) to form 
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capillary-like tube structures has been described [55]. Nevertheless, with a view to the here 
presented study these auspicious results should be applied in diabetic animal models to obtain 
reliable evidence. 
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8. Figure legends 
 
Fig. 1: Inflammatory response of the host tissue caused by the implantation of tissue-
engineered constructs. Number of rolling leukocytes, given as cells/min (A), number of 
adherent leukocytes, given as cells/mm2 (B), and macromolecular leakage as an indicator of 
microvascular permeability (C) in postcapillary and collecting venules within the border 
zones of collagen-coated (controls: white bars; diabetic mice: white bars, hatched) PLGA 
scaffolds, additionally seeded with OLCs (controls: gray bars; diabetic mice: gray bars, 
hatched) or bmMSCs (controls: dark gray bars; diabetic mice: dark gray bars, hatched) 
immediately (day 0) as well as 3, 6, 10, and 14 days after implantation into the dorsal skinfold 
chamber of BALB/c mice (any group, n=8). Means ± SEM. 
 
Fig. 2: Microvascular networks 6 days after the implantation (scaffold center: A and D; border 
zone: B, C, E, and F) in C57BL/6 (A, B, and C) and diabetic mice (D, E, and F). Intravital 
fluorescence microscopy of collagen-coated scaffolds (A and D), additionally seeded with 
OLCs (B and E) or bmMSCs (C and F). Note the considerably more densely meshed 
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microvascular networks in C57BL/6 mice. Blue light epi-illumination with contrast 
enhancement by addition of 5% FITC-labeled dextran 150,000. PLGA strands are marked 
with asterisks. 
 
Fig. 3: Time course of functional microvascular densities. Quantitative assessment of the 
functional microvascular density of newly formed microvessels, given in cm/cm2, of collagen-
coated (controls: white bars; diabetic mice: white bars, hatched) PLGA scaffolds, additionally 
seeded with OLCs (controls: gray bars; diabetic mice: gray bars, hatched) or bmMSCs 
(controls: dark gray bars; diabetic mice: dark gray bars, hatched) immediately (day 0) as well 
as 3, 6, 10, and 14 days after implantation into the dorsal skinfold chamber of BALB/c mice 
(any group, n=8). Means ± SEM. *p < 0.05 versus controls with collagen-coated scaffolds and 
all diabetic groups; °p < 0.05 versus diabetic mice with collagen-coated scaffolds; +p < 0.05 
versus the same group on the previous day. 
 
Fig. 4: Histological appearance of paraffin-embedded specimens 14 days after the 
implantation into the skinfold chamber of BALB/c mice. HE staining of collagen-coated 
(controls: A and B; diabetic mice: G and H) PLGA scaffolds, additionally seeded with OLCs 
(controls: C and D; diabetic mice: I and J) or bmMSCs (controls: E and F; diabetic mice: K 
and L). Low magnification pictures (left column: A, C, E, G, I, and K) provide an overview of 
the gross appearance of the scaffolds. After 14 days, the scaffold strands (asterisks) were 
embedded in the vascularized granulation tissue. The differences in microvascular densities 
are clarified by higher magnification pictures (right column: B, D, F, H, J, and L). Arrows 
denote the vascular structures. 
 
Fig. 5: Immunohistochemical detection of CD31 as a marker of endothelial cells (arrows) in 
collagen-coated (controls: A and B; diabetic mice: G and H) PLGA scaffolds, additionally 
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seeded with OLCs (controls: C and D; diabetic mice: I and J) or bmMSCs (controls: E and F; 
diabetic mice: K and L). At day 14, a positive reaction for CD31 was detectable in all 
constructs, but marked differences in vascular density were observed depending on the 
composition of the constructs. PLGA strands are marked with asterisks. Left column (A, C, E, 
G, I, and K): overview, right column (B, D, F, H, J, and L): higher magnification. 
 
